Overview

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, parallel-controlled, multicenter, phase III study to compare the efficacy and safety of HLX15-IV in combination with Rd (HLX15-IV-Rd) versus DARZALEX in combination with Rd (D-Rd) in patients with NDMM who are ineligible for autologous stem cell transplantation (ASCT).

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

daratumumab